Satisfying needs for

niche Specialty Care products

00 / pharma& news

31/01/2022

We are proud to announce that we closed an agreement with Astellas Deutschland GmbH, (a subsidiary of Astellas Pharma Inc.) on December 31st 2021 to acquire Astellas’ worldwide rights* of Bendamustine commercialized under the brand names LEVACT®, RIBOMUSTIN® and others, securing access and continuous supply for patients benefitting from this well-established and distinguished therapy option.

For any inquiries please contact us at contact@pharmaand.com.

*) excluding Marketing Authorizations in a small number of markets, including Morocco which is subject to merger clearance.

more news /

01 / pharma& is

pharma& is a privately owned company, aiming at satisfying needs for niche, original, Specialty Care products.

Our commitment to patient access for well-established original Specialty Care medicines and our worldwide presence of own subsidiaries, affiliated companies and partnerships, secure sustainable product availibilty in markets around the world.

02 / pharma& story

After having acquired multiple products in various therapeutic areas and having established a profound base to secure patient access and to supply products across the entire European Landscape we have expanded our footprint to serve patients around the world.

We are proud of our “every patient counts” commitment and our strong partnership network.

03 / pharma& team

All of us have been trained over decades in Top Tier Global Pharmaceutical Companies, coming together as a team, committed and enjoying to grow together.

Supported by our trusted network of highly qualified service providers and experts, we want to shape our future and to leave footprints for the benefits of our patients, their caregivers and our stakeholders.